Drug Screening Finds Existing Agents with Potential Activity Against Thyroid Cancer

Share this content:

Researchers have increasingly begun to evaluate existing approved drugs for other clinical uses in an effort to circumvent the extensive process of drug discovery and development. A study accepted for publication in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM) has found that a number of drugs that are already approved for use in a broad range of therapeutic categories express an antiproliferative effect in thyroid cancer cell lines.

Using quantitative high-throughput screening of the National Institutes of Health Chemical Genomic Center's pharmaceutical collection (a compilation of 2,816 clinically approved drugs and bioactive compounds), researchers at the National Human Genome Research Institute, Bethesda, MD, found that agents with the greatest anti-cancer effectiveness within thyroid cancer cell lines included cardiotonic and antiobesity agents. Sixteen drugs had an efficacy of greater than 60% and 50% inhibitory concentration in the nanomolar range.

Results of the quantitative high-throughput screening were validated using the agents bortezomib and ouabain in cell lines with BRAF V600E, RET/PTC1, p53, and PTEN mutations, as well as different histological subtypes of thyroid cancer. Both bortezomib and ouabain induced apoptosis, and ouabain caused cell cycle arrest.

The study investigators believe that such a screening approach can lead to the discovery of novel agents in different therapeutic categories and drugs which are not currently classified as chemotherapy agents by their mechanisms of action. Furthermore, following the approach of the study may lead to drug repurposing and accelerated clinical trials of compounds with well-established pharmacokinetics and toxicity profiles. 

Zhang L, He M, Zhang Y, et al. Quantitative High-Throughput Drug Screening Identifies Novel Classes of Drugs with Anticancer Activity in Thyroid Cancer Cells: Opportunities for Repurposing.  J Clin Endocrinol Metab. 2011 Dec 14. [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs